Inventor · disambiguated record
Rui Zhang
Also filed as: ZHANG RUI · ZHANG RUI LAN
74 granted patents·38 pending applications·448 citations·filing 2000–2024
99Inventor score
Files withJANSSEN PHARMACEUTICA NV35NOVAGEN HOLDING CORP14MERCK SHARP & DOHME5SPARK THERAPEUTICS INC5WANG HAITAO5
Top patents by PatentIndex Score
112 records- 0197US11767354B2Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2021·Granted Sep 26, 2023·3 cites·23 claims
- 0297US7635718B24-((phenoxyalkyl)thio)-phenoxyacetic acids and analogsJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Dec 22, 2009·48 cites·26 claims
- 0396US10428134B2Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Oct 1, 2019·7 cites·21 claims
- 0496US8106095B24-((phenoxyalkyl)thio)-phenoxyacetic acids and analogsKUO GEE-HONG·Filed 2009·Granted Jan 31, 2012·43 cites·19 claims
- 0596US8067548B2Fusion proteins having mutated immunoglobulin hinge regionWANG HAITAO·Filed 2008·Granted Nov 29, 2011·36 cites·11 claims
- 0696US7625564B2Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2006·Granted Dec 1, 2009·41 cites·34 claims
- 0796US7301050B24-((phenoxyalkyl)thio)-phenoxyacetic acids and analogsJANSSEN PHARMACEUTICA NV·Filed 2004·Granted Nov 27, 2007·64 cites·58 claims
- 0895US11591379B2Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Feb 28, 2023·3 cites·20 claims
- 0994US10968265B2Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Apr 6, 2021·4 cites·24 claims
- 1094US10787495B2Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2019·Granted Sep 29, 2020·3 cites·20 claims
- 1194US10640544B2Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted May 5, 2020·4 cites·28 claims
- 1293US11401315B2Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Aug 2, 2022·2 cites·24 claims
- 1393US10858413B2Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Dec 8, 2020·3 cites·17 claims
- 1492US7425649B24-((phenoxyalkyl)thio)-phenoxyacetic acids and analogsJANSSEN PHARMACEUTICA NV·Filed 2005·Granted Sep 16, 2008·20 cites·40 claims
- 1592US2025026803A1Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 1691US10968264B2Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Apr 6, 2021·2 cites·31 claims
- 1791US10961293B2Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Mar 30, 2021·2 cites·14 claims
- 1891US8431132B2Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoWANG HAITAO·Filed 2009·Granted Apr 30, 2013·13 cites·23 claims
- 1991US7625555B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2007·Granted Dec 1, 2009·13 cites·34 claims
- 2090US7598416B24-((phenoxyalkyl)thio)-phenoxyacetic acids and analogsJANSSEN PHARMACEUTICA NV·Filed 2008·Granted Oct 6, 2009·12 cites·18 claims
- 2190US7135498B1Nitric oxide donors for inducing neurogenesisFORD HENRY HEALTH SYSTEM·Filed 2000·Granted Nov 14, 2006·30 cites·3 claims
- 2289US2024018208A1Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptorsJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 2386US9586948B2Inhibitors of IRAK4 activityMERCK SHARP & DOHME·Filed 2013·Granted Mar 7, 2017·7 cites·3 claims
- 2486US9375487B2Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2013·Granted Jun 28, 2016·5 cites·10 claims
- 2586US8003795B2Compounds and compositions for reducing lipid levelsCVI PHARMACEUTICALS LTD·Filed 2008·Granted Aug 23, 2011·19 cites·25 claims
- 2686US2023210808A14-(phenoxyalkyl)thio)-phenoxyacetic acids and analogsJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 2786US2023365644A1Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptorsJANSSEN PHARMACEUTICA NV·Filed 2023·Application pending·0 cites
- 2884US11279742B2Recombinant human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2018·Granted Mar 22, 2022·1 cites·20 claims
- 2984US8425895B2Recombinant human interferon-like proteinsWANG HAITAO·Filed 2007·Granted Apr 23, 2013·4 cites·48 claims
- 3084US7964375B2Polynucleotides encoding human EPO-FC fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2009·Granted Jun 21, 2011·4 cites·11 claims
- 3184US7655423B2Nitric oxide donors for inducing neurogenesisFORD HENRY HEALTH SYSTEM·Filed 2002·Granted Feb 2, 2010·16 cites·2 claims
- 3282US12091405B2Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitorsMERCK SHARP & DOHME LLC·Filed 2019·Granted Sep 17, 2024·2 cites·13 claims
- 3382US10214493B2Indazole derivatives useful as glucagon receptor antagonistsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Feb 26, 2019·3 cites·13 claims
- 3481US2023265143A1Recombinant human epo-fc-fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoNOVAGEN HOLDING CORP·Filed 2022·Application pending·0 cites
- 3580US11028398B2Fusion proteins having mutated immunoglobulin hinge regionWANG HAITAO·Filed 2011·Granted Jun 8, 2021·2 cites·25 claims
- 3680US10117949B2Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivoWANG HAITAO·Filed 2007·Granted Nov 6, 2018·2 cites·27 claims
- 3780US10030027B2Soluble guanylate cyclase stimulatorsMERCK SHARP & DOHME·Filed 2016·Granted Jul 24, 2018·3 cites·56 claims
- 3880US10000473B2Indazole derivatives useful as glucagon receptor antagonistsJANSSEN PHARMACEUTICA NV·Filed 2017·Granted Jun 19, 2018·3 cites·20 claims
- 3980US7868151B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2009·Granted Jan 11, 2011·2 cites·14 claims
- 4080US7598292B24-((phenoxyalkyl)thio)-phenoxyacetic acids and analogsJANSSEN PHARMACEUTICA NV·Filed 2004·Granted Oct 6, 2009·10 cites·39 claims
- 4179US11732019B2Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptorsJANSSEN PHARMACEUTICA NV·Filed 2021·Granted Aug 22, 2023·0 cites·15 claims
- 4279US9234022B2Recombinant human interferon-like proteins and method of treatment using themNOVAGEN HOLDING CORP·Filed 2013·Granted Jan 12, 2016·2 cites·42 claims
- 4379US8518997B24-(phenoxyalkyl)thio)-phenoxyacetic acids and analogsKUO GEE-HONG·Filed 2011·Granted Aug 27, 2013·2 cites·18 claims
- 4478US12134636B2Immunoglobulins and uses thereofJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Nov 5, 2024·0 cites·35 claims
- 4578US7867482B2Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2009·Granted Jan 11, 2011·2 cites·30 claims
- 4677US2024117000A1Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereofJANSSEN SCIENCES IRELAND UNLIMITED CO·Filed 2023·Application pending·0 cites
- 4773US10118900B2Benzimidazole derivatives useful as CB-1 inverse agonistsJANSSEN PHARMACEUTICA NV·Filed 2016·Granted Nov 6, 2018·1 cites·14 claims
- 4873US2020369741A1Recombinant human interferon-like proteinsNOVAGEN HOLDING CORP·Filed 2019·Application pending·0 cites
- 4970US2019192475A14-(phenoxyalkyl)thio)-phenoxyacetic acids and analogsJANSSEN PHARMACEUTICA NV·Filed 2019·Application pending·0 cites
- 5069US11098016B2Indazole derivatives useful as glucagon receptor antagonistsJANSSEN PHARMACEUTICA NV·Filed 2020·Granted Aug 24, 2021·0 cites·12 claims
Showing the top 50 of 112 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →